Kevin D. McCormick
Kevin D. McCormick has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Michael Berlin
Institute of Pharmacology, Heidelberg University, Heidelberg, Germany
3 shared publications Robert Aslanian
Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ, 07033, USA
2 shared publicationsShirley M. Williams
Chemical Research, Cardiovascular/Metabolic Diseases and CNS Discovery, and Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Kenilworth, NJ 07033, USA
2 shared publicationsWalter Korfmacher
Chemical Research, Cardiovascular/Metabolic Diseases and CNS Discovery, and Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Kenilworth, NJ 07033, USA
2 shared publications- Yoon Joo Lee
Institute for Plant Sciences and Cluster of Excellence on Plant Sciences (CEPLAS), University of Cologne, Cologne, Germany
2 shared publications Aileen House
Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ, 07033, USA
1 shared publication
Latest Publications
- 1 April 2010
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 4 (2) , 56-61
Pharmacokinetics of Pseudoephedrine in Rats, Dogs, Monkeys and Its Pharmacokinetic-Pharmacodynamic Relationship in a Feline Model of Nasal Congestion
The objectives of these studies were to characterize the pharmacokinetics (PK) of the nasal decongestant pseudoephedrine (PSE) in rats, dogs, and monkeys, and to evaluate its lower gastrointestinal tract regional bioavailability in rats. An LC-MS/MS assay with a lower limit of quantification (LLOQ) of 0.4 ng/mL of plasma was developed for the analysis of PSE in animal plasma. The total body clearance (CL) was the highest in rats (78 mL/min/kg), lowest in monkeys (15 mL/min/kg) and the dog averaged in between (33 mL/min/kg). The volume of distribution at steady state (Vdss) ranged from 3-5 L/kg in all species. In rats and dogs, the mean half-lives (t1/2) was ∼1.5 hr, while in monkeys the mean t1/2 was 4.6 hr, comparable to that observed in adult humans (4-8 hr). The oral bioavailability was 38, 58 and 87% in rats, dogs and monkeys. The bioavailability following intra-ileum or intra-colonic administration in rats was superior to that following oral dosing (66% and 78%, respectively) suggesting that colonic absorption may be compensating for the short half-life, thus enabling successful QD sustained release formulations of PSE. The pharmacokinetic/pharmacodynamic relationship (PK/PD) of PSE was also investigated in a feline model of nasal congestion to establish efficacious trough concentrations in cats for a comparison with that in humans. The PK/PD in the cat model followed a sigmoid Emax model with an EC50 (plasma concentration that elicits 50% of the maximum response) of 0.32 ± (0.05) (SD) μM consistent with human plasma concentrations required for efficacy.
- 1 April 2010
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 4 (2) , 56-61
Pharmacokinetics of Pseudoephedrine in Rats, Dogs, Monkeys and Its Pharmacokinetic-Pharmacodynamic Relationship in a Feline Model of Nasal Congestion
The objectives of these studies were to characterize the pharmacokinetics (PK) of the nasal decongestant pseudoephedrine (PSE) in rats, dogs, and monkeys, and to evaluate its lower gastrointestinal tract regional bioavailability in rats. An LC-MS/MS assay with a lower limit of quantification (LLOQ) of 0.4 ng/mL of plasma was developed for the analysis of PSE in animal plasma. The total body clearance (CL) was the highest in rats (78 mL/min/kg), lowest in monkeys (15 mL/min/kg) and the dog averaged in between (33 mL/min/kg). The volume of distribution at steady state (Vdss) ranged from 3-5 L/kg in all species. In rats and dogs, the mean half-lives (t1/2) was ∼1.5 hr, while in monkeys the mean t1/2 was 4.6 hr, comparable to that observed in adult humans (4-8 hr). The oral bioavailability was 38, 58 and 87% in rats, dogs and monkeys. The bioavailability following intra-ileum or intra-colonic administration in rats was superior to that following oral dosing (66% and 78%, respectively) suggesting that colonic absorption may be compensating for the short half-life, thus enabling successful QD sustained release formulations of PSE. The pharmacokinetic/pharmacodynamic relationship (PK/PD) of PSE was also investigated in a feline model of nasal congestion to establish efficacious trough concentrations in cats for a comparison with that in humans. The PK/PD in the cat model followed a sigmoid Emax model with an EC50 (plasma concentration that elicits 50% of the maximum response) of 0.32 ± (0.05) (SD) μM consistent with human plasma concentrations required for efficacy.
- 1 April 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (7) , 2359-2364
Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists
- 1 April 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (7) , 2359-2364
Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists
- 1 March 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (6) , 937-941
Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template
- 1 March 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (6) , 937-941
Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template